Clinical Implications of Neuroendocrine Tumors

  • George C. Nikou


Neuroendocrine tumors may be functioning or nonfuctioning and symptoms may be caused by mechanical effects of the tumor itself or by the systemic effects of tumor hormonal products. In patients with nonfunctioning, more often pancreatic, neuroendocrine tumors, the presenting symptoms are not specific and may be associated with a tumor growth or the development of metastases. Neuroendocrine tumors represent a very heterogenous group of neoplasms and their clinical behaviour is extremely variable, ranging from slow-growing tumors, which is the majority, to highly aggressive and very malignant tumors. Furthermore, and this is probably due to the fact that these tumors are rather rare, often with slow evolution, that they are many times diagnosed once they already have metastases.


  1. 1.
    Nikou GC, Pazaitou-Panayiotou K, Dimitroulopoulos D et al (2016) Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients. BMC Endocr Disord 16:8.
  2. 2.
    Bhattacharyya S, Toumpanakis C, Chilkunda D (2011) Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol 107(8):1221–1226CrossRefGoogle Scholar
  3. 3.
    Nikou GC, Lygidakis NJ, Toubanakis C et al (2005) Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-a, somatostatin receptor scintigraphy and somatostatin analogues. Hepato-Gastroenterology 52(63):731–741PubMedGoogle Scholar
  4. 4.
    Nikou GC, Toubanakis C, Moulakakis C et al (2011) Carcinoid tumors of the duodenum and the ampulla of vater: current diagnostic and therapeutic approach in a series of 8 patients. Int J Surg 9:248–253CrossRefGoogle Scholar
  5. 5.
    Nikou GC, Toubanakis C, Nikolaou P et al (2005) Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients. Hepato-Gastroenterology 52(66):1668–1676PubMedGoogle Scholar
  6. 6.
    Nikou GC, Toubanakis C, Nikolaou P (2005) VIPomas: an update in diagnosis and management in a series of 11 patients. Hepato-Gastroenterology 52(64):1259–1265PubMedGoogle Scholar
  7. 7.
    Hemminki K, Li X (2001) Incidence trands and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 92:2204–2210CrossRefGoogle Scholar
  8. 8.
    Bushnell DL, Baum RP (2011) Standard imaging techniques for neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1):153–162CrossRefGoogle Scholar
  9. 9.
    Kwekkeboom DJ, Krenning EP, Scheidhauer K et al (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: somatostatin receptor imaging with (111)in- pentetreotide. Neuroendocrinology 90(2):184–189CrossRefGoogle Scholar
  10. 10.
    Miederer M, Weber MM, Fottner C (2010) Molecular imaging of gastroenteropancreatic neuroendocrine tumors. Gastroenterol Clin N Am 39(4):923–935CrossRefGoogle Scholar
  11. 11.
    Nikou GC, Marinou K, Thomakos P et al (2008) Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology 8:510–519CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • George C. Nikou
    • 1
  1. 1.Section of Neuroendocrine Tumors, National and Kapodistrian University of AthensSotiria Hospital, Medical School of Athens UniversityAthensGreece

Personalised recommendations